Skip to main content
News

Prognostic Significance of Time to POD, Ki67, and MIPI for Patients With R/R Mantle Cell Lymphoma Initiating Second-Line BTK Inhibitor Therapy

Jordan Kadish

Time to progression of disease (POD), proliferation marker Ki67, and Mantle Cell Lymphoma International Prognostic Index (MIPI) were strongly associated with survival outcomes among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who initiated second-line Bruton’s tyrosine kinase (BTK) inhibitor treatment after first-line rituximab-containing therapy, according to findings from a study published in Blood Advances. 

Diego Villa, MD, University of British Columbia, Vancouver, Canada, and coauthors stated that although time to POD after first-line therapy is already an established prognostic factor in MCL, previous “studies have included a broad range of [first-line], second[-line] and subsequent lines of therapy.” The current study aimed to identify prognostic factors among patients with R/R MCL exclusively initiating second-line BTK inhibitors after first-line rituximab-containing therapy.

A total of 360 patients were included from 8 international centers, comprising 160 patients in the main cohort and 200 in the validation cohort. Multivariable models were utilized to assess the association between time to POD and various clinical/pathological factors. Nomograms and prognostic indexes were developed to predict progression-free survival (PFS) and overall survival (OS) following the initiation of second-line BTK inhibitor therapy. 

Results identified that time to POD, Ki67 ≥30%, and MIPI were key factors significantly associated with PFS and OS from the start of second-line BTK inhibitor therapy. C-indexes collected from the constructed models consistently demonstrated values of ≥0.68 for both the main and validation cohorts. Based on these findings, web/application-based calculators were developed using the nomograms and prognostic indexes to estimate PFS and OS. The second-line BTK inhibitor therapy MIPI classified patients into 3 risk groups with varying 2-year PFS rates, including high-risk (14%), intermediate-risk (50%), and low-risk (64%).

In conclusion, Villa et al stated, “Time to POD, Ki67, and MIPI were strongly associated with outcomes in patients with R/R MCL receiving [second-line] BTK inhibitor therapy. Given the generally aggressive biology of MCL, the identification of such factors could assist in the design of future studies of therapies for R/R MCL.”

“Simple clinical models incorporating these variables may assist in planning for alternative therapies such as chimeric antigen receptor T-cell (CAR T-cell) therapy, allogeneic stem cell transplantation, or novel agents with alternative mechanisms of action,” they added. 


Source: 

Villa D, Jiang A, Visco C, et al. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. Published online June 13, 2023. doi:10.1182/bloodadvances.2023009804